Alector is a speculative biotech play, with key catalysts ahead in partnership with GlaxoSmithKline. Topline data from the pivotal phase 3 INFRONT-3 trial of latozinemab in FTD-GRN is expected in Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback